Hypoxia and anaemia in patients with cancer of the uterine cervix.
Hypoxia and/or anaemia have an adverse prognostic impact in locally-advanced cancers of uterine cervix. Moreover, these parameters are independent of other well-known prognostic factors. However, the mechanisms by which treatment efficacy and survival are compromised by anaemia are not fully understood. Although it is clear that erythropoietin can reduce the need for transfusions for cancer patients with anaemia, there is no proof that the use of erythropoietin is in any way superior to transfusions with respect to the impact on clinical outcome, especially for patients receiving radiation therapy. Whether haemoglobin levels at the start of therapy, during therapy, or at the end of therapy are of prognostic value for better disease-free and overall survival, are matters for further studies as is the question of the best option for increasing the level of the patient's haemoglobin.
Andreu-Martínez
Francisco José
FJ
Servicio de Oncología Radioterápica, Hospital Universitari Sant Joan, Crta. Ncnal. 332 Alacant/València s/n, 03550 Sant Joan d'Alacant, Alicante, Spain. andreu_fra@gva.es
Martínez-Mateu
Julia M
JM
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000860:Hypoxia / Q000209:etiology*; D014594:Uterine Neoplasms / Q000150:complications*
D004921:Erythropoietin